NEW YORK (Reuters Health) – Bevacizumab improved visual acuity and
Bevacizumab an Option for Diabetic Macular Edema
NEW YORK (Reuters Health) – Bevacizumab improved visual acuity and
Combo Shows ‘Impressive’ Survival Results in First-Line RCC
The combination of lenvatinib and pembrolizumab outperforms sunitinib as first-line
Bevacizumab may cause cognitive impairment
Glioblastoma is the most common kind of brain tumour in